Pregabalin Capsule
Product Images NDC 50090-6793

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-6793). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906793)

Packaging label for PREGABALIN 75 mg capsules by A-S Medication Solutions. The label shows the drug name, strength of 75 mg, dosage form as capsules, and a quantity of 90 capsules. It includes storage instructions to keep between 68 to 77 degrees Fahrenheit and displays a QR code and NDC 50090-6793.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of pregabalin, showing the molecular formula arrangement including an amino group (NH2) and a carboxylic acid group (CO2H) attached to a hydrocarbon backbone.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula for calculating creatinine clearance (CLCr), adjusted for age, weight, serum creatinine levels, and gender (with a factor for female patients). This text relates to pharmacokinetic calculations relevant to the drug Pregabalin.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting the percent of patients improved plotted against the percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing varied efficacy in pain improvement by dosage.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A chart showing the percent of patients improved versus percent improvement in pain from baseline comparing Pregabalin 100 mg three times a day against placebo. The graph plots two lines, with Pregabalin consistently showing higher patient improvement percentages across increasing pain improvement levels.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses (75 mg, 150 mg, and 300 mg twice a day) compared to placebo. The y-axis shows percent of patients improved, and the x-axis shows percent pain improvement, illustrating efficacy differences among doses and placebo.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows higher percentages of patients improved with Pregabalin compared to placebo across various levels of pain improvement.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo, showing trends in patient improvement percentages across different pain improvement thresholds.*

FDA Label Image

Pregabalin-fig-06 (Pregabalin Fig 06)

A bar chart comparing responder rates (%) for different doses of pregabalin and placebo in two studies, E1 and E3. Study E1 shows rates across placebo, 50 mg, 150 mg, 300 mg, and 600 mg daily doses, while Study E3 compares placebo, 600 mg twice daily, and 600 mg three times daily doses. Each bar is labeled with the number of participants, and statistically significant differences from placebo are indicated.*

FDA Label Image

Pregabalin-fig-07 (Pregabalin Fig 07)

A line graph depicting seizure reduction (median % change from baseline) on the y-axis versus dose in mg/day on the x-axis. Four data series are shown for different studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with significance p-values indicated for various dose points. The legend identifies the four study groups by distinct markers.*

FDA Label Image

Pregabalin-fig-08 (Pregabalin Fig 08)

Bar chart showing responder rates (%) for three groups: Placebo (22.6%, n=93), 2.5 mg/kg/day (29.1%, n=103), and 10 mg/kg/day (40.6%, n=96). The vertical axis represents responder rate percentages ranging from 0 to 60%.*

FDA Label Image

Pregabalin-fig-09 (Pregabalin Fig 09)

A line graph showing percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. Four lines represent different treatment groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and Placebo, indicating comparative patient pain improvement across these groups.*

FDA Label Image

Pregabalin-fig-10 (Pregabalin Fig 10)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR over a period of 180 days. Two lines compare Pregabalin and Placebo groups, with the Pregabalin group generally showing higher estimated survival percentages compared to Placebo.*

FDA Label Image

Pregabalin-fig-11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved from baseline to week 12 between Pregabalin and placebo groups. The x-axis shows percentage improvement, while the y-axis indicates the percent of subjects improved. Pregabalin shows a higher improvement rate across the range compared to placebo.*

FDA Label Image

Pregabalin-fig-12 (Pregabalin Fig 12)

A line graph comparing the percent of subjects improved from baseline to week 16 using BOCF method between Pregabalin and placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved. Pregabalin shows a higher percentage of subjects improved across different improvement levels compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.